CytomX Therapeutics, Inc. (CTMX) Financials

CTMX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 359.4 million 39.4 million
Dec. 31, 2025 151.6 million 52.6 million
Sept. 30, 2025 158.3 million 50.9 million
June 30, 2025 175.1 million 55.1 million

CTMX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -25.5 million 4.7 million
Dec. 31, 2025 -23.4 million 1.5 million
Sept. 30, 2025 -15.4 million 1.5 million
June 30, 2025 -15.8 million 1.4 million

CTMX Net Income

No data available :(

CTMX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 346.7 million - -
Dec. 31, 2025 137.1 million - 4.2 million
Sept. 30, 2025 143.6 million - 5.6 million
June 30, 2025 158.1 million - 6.9 million

CTMX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 177.3 million
Dec. 31, 2025 170.2 million
Sept. 30, 2025 165.0 million
June 30, 2025 129.1 million

CTMX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 19.2 million 10.7 million -
Dec. 31, 2025 201000 21.2 million 7.4 million -
Sept. 30, 2025 127000 15.3 million 6.4 million -
June 30, 2025 27000 13.3 million 6.6 million -

CTMX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 10.3 million 251000
Dec. 31, 2025 663000 510000
Sept. 30, 2025 6.0 million -
June 30, 2025 18.7 million 347000

CTMX Revenue by Segment
Graph available only for paid members. Upgrade to see it.

CTMX

Price: $2.92

52 week price:
1.72
8.21

Payout Ratio Range:
-58.37%
-11.32%

Earnings Per Share: -0.52 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 865300

Ebitda: -10.5 million

Market Capitalization: 482.5 million

Links: